B16/BL6 melanoma TILs, secondary resistance, mouse M1
strain
C57BL/6
isolate
not collected
breed
not collected
cultivar
not collected
ecotype
not collected
age
approx. 10-15 weeks at collection
dev_stage
adult
collection_date
2020-12-01
geo_loc_name
United Kingdom: London
sex
female
tissue
melanoma tumor
biomaterial_provider
UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, UK
collected_by
Quezada laboratory, UCL Cancer Institute
disease
melanoma
genotype
wild type
growth_protocol
50,000 B16/BL6 melanoma cells implanted intradermally (right flank) on day 0; 200 ug anti-CD25(NIB) Treg-depleting antibody i.p. on day 5; 1e6 irradiated (150 Gy) GM-CSF-expressing B16 (GVAX) cells i.d. contralateral flank on days 6, 9, 12
health_state
tumor-bearing
isolation_source
B16/BL6 melanoma tumor, intradermal, right flank
treatment
anti-CD25(NIB) Treg-depleting antibody + irradiated GM-CSF-expressing B16 (GVAX) cancer-cell vaccine
tumor_model
B16/BL6 melanoma (intradermal, C57BL/6)
response_phase
secondary resistance (2R, relapse)
collection_timepoint
secondary resistance / relapse (tumor volume >400 mm3),, mouse 1
sorted_populations
Tumor-infiltrating T cells (sorted live CD45+CD3+CD5+) and myeloid/non-T-non-B cells (sorted live CD45+CD5-CD19-), processed as separate 10x libraries from the same tumor
assay
10x Chromium Next GEM 5' scRNA-seq + paired scTCR-seq (V(D)J)
BioSampleModel
Model organism or animal